<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39407710</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>16</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>19</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1420-3049</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>19</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>09</Day></PubDate></JournalIssue><Title>Molecules (Basel, Switzerland)</Title><ISOAbbreviation>Molecules</ISOAbbreviation></Journal><ArticleTitle>Inclusion Complexation of Remdesivir with Cyclodextrins: A Comprehensive Review on Combating Coronavirus Resistance-Current State and Future Perspectives.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">4782</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/molecules29194782</ELocationID><Abstract><AbstractText>Cyclodextrin (CD) derivatives have gained significant attention in biomedical applications due to their remarkable biocompatibility, unique inclusion capabilities, and potential for functionalization. This review focuses on recent advancements in CD-based assemblies, specifically their role in improving drug delivery, emphasizing remdesivir (RMD). The review introduces CD materials and their versatile applications in self-assembly and supramolecular assembly. CD materials offer immense potential for designing drug delivery systems with enhanced activity. Their inherent inclusion capabilities enable the encapsulation of diverse therapeutic agents, including RMD, resulting in improved solubility, stability, and bioavailability. The recent advances in CD-based assemblies, focusing on their integration with RMD have been concentrated here. Various strategies for constructing these assemblies are discussed, including physical encapsulation, covalent conjugation, and surface functionalization techniques. Furthermore, exploring future directions in these fields has also been provided. Ongoing research efforts are directed toward developing novel CD derivatives with enhanced properties, such as increased encapsulation efficiency and improved release kinetics. Moreover, the integration of CD-based assemblies with advanced technologies such as nanomedicine and gene therapy holds tremendous promise for personalized medicine and precision therapeutics.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Anitha</LastName><ForeName>Arumugam</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>PG and Research Department of Chemistry, Government Arts College, Chidambaram 608 102, Tamil Nadu, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rajamohan</LastName><ForeName>Rajaram</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-6141-9425</Identifier><AffiliationInfo><Affiliation>School of Chemical Engineering, Yeungnam University, Gyeongsan 38541, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murugan</LastName><ForeName>Moorthiraman</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Chemistry, IFET College of Engineering, Villupuram 605 108, Tamil Nadu, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seo</LastName><ForeName>Jeong Hyun</ForeName><Initials>JH</Initials><Identifier Source="ORCID">0000-0001-6970-4653</Identifier><AffiliationInfo><Affiliation>School of Chemical Engineering, Yeungnam University, Gyeongsan 38541, Republic of Korea.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Molecules</MedlineTA><NlmUniqueID>100964009</NlmUniqueID><ISSNLinking>1420-3049</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003505">Cyclodextrins</NameOfSubstance></Chemical><Chemical><RegistryNumber>3QKI37EEHE</RegistryNumber><NameOfSubstance UI="C000606551">remdesivir</NameOfSubstance></Chemical><Chemical><RegistryNumber>OF5P57N2ZX</RegistryNumber><NameOfSubstance UI="D000409">Alanine</NameOfSubstance></Chemical><Chemical><RegistryNumber>415SHH325A</RegistryNumber><NameOfSubstance UI="D000249">Adenosine Monophosphate</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D003505" MajorTopicYN="Y">Cyclodextrins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000409" MajorTopicYN="Y">Alanine</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000249" MajorTopicYN="Y">Adenosine Monophosphate</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="Y">Antiviral Agents</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="Y">COVID-19 Drug Treatment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016503" MajorTopicYN="N">Drug Delivery Systems</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">cyclodextrins</Keyword><Keyword MajorTopicYN="N">inclusion complexes</Keyword><Keyword MajorTopicYN="N">remdesivir</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>10</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>16</Day><Hour>10</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>16</Day><Hour>10</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>16</Day><Hour>1</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>9</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39407710</ArticleId><ArticleId IdType="pmc">PMC11477750</ArticleId><ArticleId IdType="doi">10.3390/molecules29194782</ArticleId><ArticleId IdType="pii">molecules29194782</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>DeClercq E. Strategies in the design of antiviral drugs. Nat. Rev. Drug Discov. 2002;1:13–25. doi: 10.1038/nrd703.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd703</ArticleId><ArticleId IdType="pubmed">12119605</ArticleId></ArticleIdList></Reference><Reference><Citation>McCormack S., Ramjee G., Kamali A. PRO2000 vaginal gel for prevention of HIV-1 infection (microbicides development programme 301): Phase 3, randomised, double-blind, parallel-group trial. Lancet. 2010;376:1329–1337. doi: 10.1016/S0140-6736(10)61086-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(10)61086-0</ArticleId><ArticleId IdType="pmc">PMC2956883</ArticleId><ArticleId IdType="pubmed">20851460</ArticleId></ArticleIdList></Reference><Reference><Citation>Pirrone V., Wigdahl B., Krebs F.C. The rise and fall of polyanionic inhibitors of the human immunodeficiency virus type 1. Antivir. Res. 2011;90:168–182. doi: 10.1016/j.antiviral.2011.03.176.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2011.03.176</ArticleId><ArticleId IdType="pubmed">21439325</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Damme L.R., Govinden R.F.M., Mirembe F.M.F. Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission. N. Engl. J. Med. 2008;359:463–472. doi: 10.1056/NEJMoa0707957.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa0707957</ArticleId><ArticleId IdType="pubmed">18669425</ArticleId></ArticleIdList></Reference><Reference><Citation>Wieslaw M.K. Antiviral Drugs: From Basic Discovery through Clinical Trials. John Wiley &amp; Sons; Hoboken, NJ, USA: 2011.</Citation></Reference><Reference><Citation>Laila R., Sunny O.A., Amanuel G.A., Mickael E., Aliyu Tijani J., Andrzej F., Robert F., Rangarirai M., Leander M., Kawthar M., et al. Oral antiviral treat-ments for COVID-19: Opportunities and challenges. Pharm. Rep. 2022;74:1255–1278.</Citation></Reference><Reference><Citation>Daisy Y., Bingfang Y. Viral target and metabolism-based rationale for combined use of recently authorized small molecule COVID-19 medicines: Molnupiravir, nirmatrelvir, and remdesivir. Fund. Clin. Pharmacol. 2023;37:726–738.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10505250</ArticleId><ArticleId IdType="pubmed">36931725</ArticleId></ArticleIdList></Reference><Reference><Citation>Faez I., Tongzhou K., Haider A., Dakun L. Remdesivir Strongly Binds to RNA-Dependent RNA Polymerase, Membrane Protein, and Main Protease of SARS-CoV-2: Indi-cation From Molecular Modeling and Simulations. Front. Pharmacol. 2021;12:710778.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8293383</ArticleId><ArticleId IdType="pubmed">34305617</ArticleId></ArticleIdList></Reference><Reference><Citation>Parums D.V. Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Patients. Med. Sci. Monit. 2022;28:e935952-61. doi: 10.12659/MSM.935952.</Citation><ArticleIdList><ArticleId IdType="doi">10.12659/MSM.935952</ArticleId><ArticleId IdType="pmc">PMC8729033</ArticleId><ArticleId IdType="pubmed">34972812</ArticleId></ArticleIdList></Reference><Reference><Citation>Jayk Bernal A., Gomes da Silva M.M., Musungaie D.B., Kovalchuk E., Gonzalez A., Delos Reyes V. Molnupiravir for Oral Treatment of COVID-19 in Nonhospitalized Patients. N. Engl. J. Med. 2022;386:509–520. doi: 10.1056/NEJMoa2116044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2116044</ArticleId><ArticleId IdType="pmc">PMC8693688</ArticleId><ArticleId IdType="pubmed">34914868</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahase E. COVID-19: UK becomes first country to authorise antiviral molnupiravir. BMJ. 2021;375:n2697. doi: 10.1136/bmj.n2697.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n2697</ArticleId><ArticleId IdType="pubmed">34737216</ArticleId></ArticleIdList></Reference><Reference><Citation>Ledford H. COVID antiviral pills: What scientists still want to know. Nature. 2021;599:358–359. doi: 10.1038/d41586-021-03074-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41586-021-03074-5</ArticleId><ArticleId IdType="pubmed">34759341</ArticleId></ArticleIdList></Reference><Reference><Citation>Owen D.R., Allerton C.M.N., Anderson A.S., Aschenbrenner L., Avery M., Berritt S. An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19. Science. 2021;374:1586–1593. doi: 10.1126/science.abl4784.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abl4784</ArticleId><ArticleId IdType="pubmed">34726479</ArticleId></ArticleIdList></Reference><Reference><Citation>Hannah A. Blair, Remdesivir: A Review in COVID-19. Drugs. 2023;83:1215–1237.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10474216</ArticleId><ArticleId IdType="pubmed">37589788</ArticleId></ArticleIdList></Reference><Reference><Citation>Michael K.L., César G.A., Jason K.P., Silvia C., Egor P.T., Lisa G., Ayan C., Punya S.-R., Payel C., Laura K.M., et al. Remdesivir targets a structurally analogous region of the Ebola virus and SARS-CoV-2 polymerases. Proc. Natl. Acad. Sci. USA. 2020;117:26946–26954.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7604432</ArticleId><ArticleId IdType="pubmed">33028676</ArticleId></ArticleIdList></Reference><Reference><Citation>Chun B.K., Clarke M.O., Doerffler E., Hui H.C., Jordan R., Mackman R.L., Parrish J.P., Ray A.S., Siegel D. Methods for Treating Filoviridae Virus Infections. 9724360. U.S. Patent. 2016 May 5;</Citation></Reference><Reference><Citation>Clarke M.O., Jordan R., Mackman R.L., Ray A.S., Siegel D. Preparation of Amino Acid-Containing Nucleosides for Treating Flaviviridae Virus Infections. WO 2017184668. 2017 October 26;</Citation></Reference><Reference><Citation>U.S. Food and Drug Administration Approves Gilead’s Antiviral Veklury (Remdesivir) for Treatment of COVID-19 (Press Release) Gilead Sciences, Inc.; Foster City, CA, USA: 2020.</Citation></Reference><Reference><Citation>Reuters . India Approves Emergency Use of Remdesivir to Treat COVID-19 Patients. Reuters; New York, NY, USA: 2020. The Times of India, Times Internet.</Citation></Reference><Reference><Citation>Reuters . Singapore Approves Remdesivir Drug for Emergency COVID-19 Treatment. Reuters; New York, NY, USA: 2020.</Citation></Reference><Reference><Citation>Pharmaceutical-Technology . Japanese Regulator Approves Gilead’s Remdesivir to Treat COVID-19. Pharmaceutical-Technology; Oxfordshire, UK: 2020.</Citation></Reference><Reference><Citation>European Medicines Agency (EMA) Veklury EPAR. European Medicines Agency (EMA); Amsterdam, The Netherlands: 2020.</Citation></Reference><Reference><Citation>Gilead Sciences . Gilead Announces Approval of Veklury (remdesivir) in Japan for Patients with Severe COVID-19 (Press Release) Gilead Sciences; Foster City, CA, USA: 2020.</Citation></Reference><Reference><Citation>U.S. Food and Drug Administration (FDA) Remdesivir EUA Letter of Authorization. U.S. Food and Drug Administration (FDA); Silver Spring, MD, USA: 2020.</Citation></Reference><Reference><Citation>U.S. Food and Drug Administration (FDA) Coronavirus (COVID-19) Update: FDA Issues Emergency Use Authorization for Potential COVID-19 Treatment (Press Release) U.S. Food and Drug Administration (FDA); Silver Spring, MD, USA: 2020.</Citation></Reference><Reference><Citation>The Asahi Shimbun . Japan Approves Remdesivir for COVID-19 Despite Uncertainties. The Asahi Shimbun; Osaka, Japan: 2020.</Citation></Reference><Reference><Citation>Therapeutic Goods Administration (TGA) Australia’s First COVID Treatment Approved. Therapeutic Goods Administration (TGA); Canberra, Australia: 2020. Press Release;</Citation></Reference><Reference><Citation>U.S. Food and Drug Administration (FDA) Veklury: FDA-Approved Drugs. U.S. Food and Drug Administration (FDA); Silver Spring, MD, USA: 2020.</Citation></Reference><Reference><Citation>U.S. Food and Drug Administration (FDA) Veklury: Summary Review. U.S. Food and Drug Administration (FDA); Silver Spring, MD, USA: 2019.</Citation></Reference><Reference><Citation>European Medicines Agency (EMA) EMA Starts Evaluating Use of Veklury in COVID-19 Patients Not Requiring Supplemental Oxygen (Press Release) European Medicines Agency (EMA); Amsterdam, The Netherlands: 2021.</Citation></Reference><Reference><Citation>Warren T.K., Jordan R., Lo M.K., Ray A.S., Mackman R.L., Soloveva V., Siegel D., Perron M., Bannister R., Hui H.C., et al. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature. 2016;531:381–385. doi: 10.1038/nature17180.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature17180</ArticleId><ArticleId IdType="pmc">PMC5551389</ArticleId><ArticleId IdType="pubmed">26934220</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilead R. Summary on Compassionate Use. European Medicines Agency; Amsterdam, The Netherlands: 2020.</Citation></Reference><Reference><Citation>Stephens B. The Story of Remdesivir. The New York Times; New York, NY, USA: 2020. p. A23.</Citation></Reference><Reference><Citation>Final Report Confirms Remdesivir Benefits for COVID-19. National Institutes of Health (NIH); Bethesda, MD, USA: 2020. Press Release.</Citation></Reference><Reference><Citation>Czech News Agency . Did Czech Scientists Create the Cure for Coronavirus? Czech News Agency; Prague, Czech Republic: 2020.</Citation></Reference><Reference><Citation>Lo M.K., Jordan R., Arvey A., Sudhamsu J., Shrivastava-Ranjan P., Hotard A.L. GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, and Paramyxoviruses. Sci. Rep. 2017;7:43395. doi: 10.1038/srep43395.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep43395</ArticleId><ArticleId IdType="pmc">PMC5338263</ArticleId><ArticleId IdType="pubmed">28262699</ArticleId></ArticleIdList></Reference><Reference><Citation>Silverman E. U.S. Government Contributed Research to a Gilead Remdesivir Patent—But Didn’t Get Credit. STAT News; Los Angeles, CA, USA: 2020.</Citation></Reference><Reference><Citation>Ardizzone K. Role of the Federal Government in the Development of Remdesivir. Knowledge Ecology International; Chicago, IL, USA: 2020.</Citation></Reference><Reference><Citation>Savannah K. Investigational Compound Remdesivir, Developed by UAB and NIH Researchers, Being Used for Treatment of Novel Coronavirus. UAB News; Birmingham, AL, USA: 2020.</Citation></Reference><Reference><Citation>Eastman R.T., Roth J.S., Brimacombe K.R., Simeonov A., Shen M., Patnaik S., Hall M.D. Remdesivir: A Review of Its Discovery and Development Leading to Emergency Use Authorization for Treatment of COVID-19. ACS Cent. Sci. 2020;6:672–683. doi: 10.1021/acscentsci.0c00489.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acscentsci.0c00489</ArticleId><ArticleId IdType="pmc">PMC7202249</ArticleId><ArticleId IdType="pubmed">32483554</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheikholeslami S.M., Jahanbani A., Shao Z. On the molecular structure of Remdesivir for the treatment of COVID-19. Comp. Meth Biomech. Biomed. Eng. 2021;24:995–1002. doi: 10.1080/10255842.2020.1863380.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/10255842.2020.1863380</ArticleId><ArticleId IdType="pubmed">33356621</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheahan T.P., Sims A.C., Graham R.L., Menachery V.D., Gralinski L.E., Case J.B. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci. Trans. Med. 2017;9:l3653. doi: 10.1126/scitranslmed.aal3653.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aal3653</ArticleId><ArticleId IdType="pmc">PMC5567817</ArticleId><ArticleId IdType="pubmed">28659436</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang M., Cao R., Zhang L., Yang X., Liu J., Xu M., Shi Z., Hu Z., Zhong W., Xiao G. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30:269–271. doi: 10.1038/s41422-020-0282-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41422-020-0282-0</ArticleId><ArticleId IdType="pmc">PMC7054408</ArticleId><ArticleId IdType="pubmed">32020029</ArticleId></ArticleIdList></Reference><Reference><Citation>Szejtli J., Osa T. Comprehensive Supramolecular Chemistry. Volume 3 J. M. Lehn Pergamon Press; Oxford, UK: 1996.</Citation></Reference><Reference><Citation>Ali Aboel D. Rapid analysis of drug binding to β-cyclodextrin: Part II substituents effect on physicochemical and co-conformational stability of drug/cyclodextrin complex. RSC Adv. 2014;4:6624–6637.</Citation></Reference><Reference><Citation>Diez M.A., Pena I.M.A., Garera M.C.M., Gil D.B., Canada F.C. Fluorimetric Determination of Sulphaguanidine and Sulphamethoxazole by Host-Guest Complexation in β-Cyclodextrin and Partial Least Squares Calibration. J. Flu. 2007;17:309–318. doi: 10.1007/s10895-007-0174-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10895-007-0174-4</ArticleId><ArticleId IdType="pubmed">17393284</ArticleId></ArticleIdList></Reference><Reference><Citation>Radi A.-E.M., Eissa S.H. Voltametric and spectrophotometric studies on the inclusion complex of glipizide with β-CD. Eur. J. Anal. Chem. 2011;6:13–21.</Citation></Reference><Reference><Citation>Cusola O., Tabary N., Belgacem M.N., Bras J. Cyclodextrin functionalization of several cellulosic substrates for prolonged release of antibacterial agents. J. Appl. Pol. Sci. 2013;129:604–613. doi: 10.1002/app.38748.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/app.38748</ArticleId></ArticleIdList></Reference><Reference><Citation>Linare M., Bertorello M.M., Longhi M. Preparation and characterization of solid complexes of Naphtoquinone and Hydroxypropyl-b-cyclodextrin. Molecules. 2000;5:342–344. doi: 10.3390/50300342.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/50300342</ArticleId></ArticleIdList></Reference><Reference><Citation>Kyeong R.R., Ji W.H. Chemical Interface Damping of Silver-coated Gold Nanorods Using Supramolecular Host–Guest Chemistry. Bull. Korean Chem. Soc. 2021;42:1082–1084.</Citation></Reference><Reference><Citation>Sota T., Tomoyuki U., Mayuko K., Motoki K., Daisuke S., Satoru M., Manabu A., Takeharu H., Takayuki E., Fuminori M., et al. Conformation of K+ (Crown Ether) Complexes Revealed by Ion Mobility–Mass Spectrometry and Ultraviolet Spectroscopy. J. Phys. Chem. A. 2020;124:9980–9990.</Citation><ArticleIdList><ArticleId IdType="pubmed">33206525</ArticleId></ArticleIdList></Reference><Reference><Citation>Paul M., Scott J.D., Martin J.P. Transition Metal Complexes of Calix[4]arene: Theoretical Investigations into Small Guest Binding within the Host Cavity. J. Phys. Chem. A. 2016;120:824–839.</Citation><ArticleIdList><ArticleId IdType="pubmed">26783648</ArticleId></ArticleIdList></Reference><Reference><Citation>Ju B.C., Jae S.H., Cheal K. Crown-Ether Type Chemosensor for the Determination of Fe3+/2+ by a Colorimetric Method. Bull. Korean Chem. Soc. 2021;42:1368–1374.</Citation></Reference><Reference><Citation>Jumina I., Amalina S., Triono Y.S., Kurniawan Y.P., Keisuke O., Bohari M.Y. Preliminary Investigation of Organocatalyst Activity Based on C-Arylcalix[4]-2-Methylresorcinarene Sulfonic Acid Materials for Biodiesel Production. Bull. Korean Chem. Soc. 2021;42:4093–4409. doi: 10.1002/bkcs.12194.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/bkcs.12194</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Valle E.M. Cyclodextrins and their uses: A review. Process Biochem. 2004;39:1033–1046. doi: 10.1016/S0032-9592(03)00258-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0032-9592(03)00258-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh M., Sharma R., Banerjee U. Biotechnological applications of cyclodextrins. Biotechnol. Adv. 2002;20:341–359. doi: 10.1016/S0734-9750(02)00020-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0734-9750(02)00020-4</ArticleId><ArticleId IdType="pubmed">14550020</ArticleId></ArticleIdList></Reference><Reference><Citation>Antía G.P., Maria C., Paula G.O., Juan C.M., Miguel A.P., Jesus S.G. Main Applications of Cyclodextrins in the Food Industry as the Compounds of Choice to Form Host–Guest Complexes. Int. J. Mol. Sci. 2021;22:1339. doi: 10.3390/ijms22031339.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22031339</ArticleId><ArticleId IdType="pmc">PMC7866268</ArticleId><ArticleId IdType="pubmed">33572788</ArticleId></ArticleIdList></Reference><Reference><Citation>Shery J., Anroop B.N. Cyclodextrin complexes: Perspective from drug delivery and formulation. Drug Dev. Res. 2018;79:201–217.</Citation><ArticleIdList><ArticleId IdType="pubmed">30188584</ArticleId></ArticleIdList></Reference><Reference><Citation>Szente L., Szejtli J. Highly soluble cyclodextrin derivatives: Chemistry, properties and trends in development. Adv. Drug Deli Rev. 1999;36:17–28. doi: 10.1016/S0169-409X(98)00092-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0169-409X(98)00092-1</ArticleId><ArticleId IdType="pubmed">10837706</ArticleId></ArticleIdList></Reference><Reference><Citation>Deluzio T.G.B., Penev K.I., Mequanint K. Cyclodextrin inclusion complexes as potential oxygen delivery vehicles in tissue engineering. J. Bio. Tissue Eng. 2014;4:957–966. doi: 10.1166/jbt.2014.1267.</Citation><ArticleIdList><ArticleId IdType="doi">10.1166/jbt.2014.1267</ArticleId></ArticleIdList></Reference><Reference><Citation>Frank D.W., Gray J.E., Weaver R.N. Cyclodextrin nephrosis in the rat. Am. J. Pathol. 1976;83:367–382.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2032314</ArticleId><ArticleId IdType="pubmed">1266946</ArticleId></ArticleIdList></Reference><Reference><Citation>Frömming K.-H., Szejtli J. Pharmacokinetics and toxicology of cyclodextrins. In: Frömming K.-H., Szejtli J., editors. Cyclodextrins in Pharmacy. Springer; Dordrecht, The Netherlands: 1994. pp. 33–44.</Citation></Reference><Reference><Citation>Szente L., Szejtli J. Cyclodextrins as food ingredients. Trends Food Sci. Technol. 2004;15:137–142. doi: 10.1016/j.tifs.2003.09.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tifs.2003.09.019</ArticleId></ArticleIdList></Reference><Reference><Citation>Loftsson T., Brewster M.E. Pharmaceutical applications of cyclodextrins: Basic science and product development. J. Pharm. Pharmacol. 2010;62:1607–1621. doi: 10.1111/j.2042-7158.2010.01030.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.2042-7158.2010.01030.x</ArticleId><ArticleId IdType="pubmed">21039545</ArticleId></ArticleIdList></Reference><Reference><Citation>Loftsson T. Effects of cyclodextrins on the chemical stability of drugs in aqueous solutions. Drug Stab. 1995;1:22–33.</Citation></Reference><Reference><Citation>Grégorio C. A History of Cyclodextrins. Chem. Rev. 2014;114:10940–10975.</Citation><ArticleIdList><ArticleId IdType="pubmed">25247843</ArticleId></ArticleIdList></Reference><Reference><Citation>Loftsson T., Hreinsdottir D., Masson M. Evaluation of cyclodextrin solubilization of drugs. Int. J. Pharm. 2005;302:18–28. doi: 10.1016/j.ijpharm.2005.05.042.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijpharm.2005.05.042</ArticleId><ArticleId IdType="pubmed">16099118</ArticleId></ArticleIdList></Reference><Reference><Citation>Loftsson T., Jarho P., Másson M., Järvinen T. Cyclodextrins in drug delivery. Expert. Opin. Drug Deliv. 2005;2:335–351. doi: 10.1517/17425247.2.1.335.</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/17425247.2.1.335</ArticleId><ArticleId IdType="pubmed">16296758</ArticleId></ArticleIdList></Reference><Reference><Citation>Challa R., Ahuja A., Ali J., Khar R.K. Cyclodextrins in drug delivery: An updated review. Pharm. Sci. Tech. 2005;6:329–357. doi: 10.1208/pt060243.</Citation><ArticleIdList><ArticleId IdType="doi">10.1208/pt060243</ArticleId><ArticleId IdType="pmc">PMC2750546</ArticleId><ArticleId IdType="pubmed">16353992</ArticleId></ArticleIdList></Reference><Reference><Citation>Biplab R., Subhadeep S., Koyeli D., Biraj K.B., Swarnab S., Arindam B., Mahendra N.R. Study to Probe Subsistence of Host-Guest Inclusion Complexes of α and β-Cyclodextrins with Biologically Potent Drugs for Safety Regulatory Dischargement. Sci. Rep. 2018;8:13031.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6115366</ArticleId><ArticleId IdType="pubmed">30158645</ArticleId></ArticleIdList></Reference><Reference><Citation>Loftsson T., Brewster M.E. Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization. J. Pharm. Sci. 1996;85:1017–1025. doi: 10.1021/js950534b.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/js950534b</ArticleId><ArticleId IdType="pubmed">8897265</ArticleId></ArticleIdList></Reference><Reference><Citation>Loftsson T., Duchene D. Cyclodextrins and their pharmaceutical applications. Int. J. Pharm. 2007;329:1–11. doi: 10.1016/j.ijpharm.2006.10.044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijpharm.2006.10.044</ArticleId><ArticleId IdType="pubmed">17137734</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogawa N., Kaga M., Endo T., Nagase H., Furuishi T., Yamamoto H., Kawashima Y., Ueda H. Quetiapine free base complexed with cyclodextrins to improve solubility for parenteral use. Chem. Pharm. Bull. 2012;61:809–815. doi: 10.1248/cpb.c13-00157.</Citation><ArticleIdList><ArticleId IdType="doi">10.1248/cpb.c13-00157</ArticleId><ArticleId IdType="pubmed">23902863</ArticleId></ArticleIdList></Reference><Reference><Citation>Szejtli J. Introduction and general overview of cyclodextrin chemistry. Chem. Rev. 1998;98:1743–1754. doi: 10.1021/cr970022c.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/cr970022c</ArticleId><ArticleId IdType="pubmed">11848947</ArticleId></ArticleIdList></Reference><Reference><Citation>Marcos L.B. Strategies to Modify the Drug Release from Pharmaceutical Systems. Elsevier Ltd.; Amsterdam, The Netherlands: 2015. pp. 87–194.</Citation></Reference><Reference><Citation>Axel F., Stefan B., Sven S., Rolf S. Degradation of raw or film-incorporated β-cyclodextrin by enzymes and colonic bacteria. Eur. J. Pharm. Biopharm. 2004;58:91–97.</Citation><ArticleIdList><ArticleId IdType="pubmed">15207542</ArticleId></ArticleIdList></Reference><Reference><Citation>Szejtli J. Past, present and future of cyclodextrin research. Pure Appl. Chem. 2004;76:1825–1845. doi: 10.1351/pac200476101825.</Citation><ArticleIdList><ArticleId IdType="doi">10.1351/pac200476101825</ArticleId></ArticleIdList></Reference><Reference><Citation>Trotta F., Loftsson T., Gaud R.S., Trivedi R., Shende P. Integration of cyclodextrins and associated toxicities: A roadmap for high quality biomedical applications. Carbohydr. Polym. 2022;295:119880. doi: 10.1016/j.carbpol.2022.119880.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.carbpol.2022.119880</ArticleId><ArticleId IdType="pubmed">35988985</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai W.-F. Cyclodextrins in non-viral gene delivery. Biomaterials. 2014;35:401–411. doi: 10.1016/j.biomaterials.2013.09.061.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biomaterials.2013.09.061</ArticleId><ArticleId IdType="pmc">PMC7112483</ArticleId><ArticleId IdType="pubmed">24103652</ArticleId></ArticleIdList></Reference><Reference><Citation>Onishi M., Ozasa K., Kobiyama K., Ohata K., Kitano M., Tanigu Chi K., Homma T., Kobayashi M., Sato A., Katakai Y., et al. Hydroxypropyl-β-cyclodextrin spikes local inflammation that induces Th2 cell and T follicular helper cell responses to the coadministered antigen. J. Immunol. 2015;194:2673–2682. doi: 10.4049/jimmunol.1402027.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1402027</ArticleId><ArticleId IdType="pmc">PMC4470223</ArticleId><ArticleId IdType="pubmed">25681338</ArticleId></ArticleIdList></Reference><Reference><Citation>Tiwari G., Tiwari R., Rai A. Cyclodextrins in delivery systems: Applications. J. Pharm. Bioallied Sci. 2010;2:72. doi: 10.4103/0975-7406.67003.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/0975-7406.67003</ArticleId><ArticleId IdType="pmc">PMC3147107</ArticleId><ArticleId IdType="pubmed">21814436</ArticleId></ArticleIdList></Reference><Reference><Citation>Subrata B., Debi P.N. Lipid raft disruption by cholesterol depletion enhances influenza A virus budding from MDCK cells. J. Virol. 2007;81:12169–12178.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2169012</ArticleId><ArticleId IdType="pubmed">17855515</ArticleId></ArticleIdList></Reference><Reference><Citation>Annamaria P., Valeriana C. Role of the lipid rafts in the life cycle of canine coronavirus. J. Gen. Virol. 2015;96:331–337.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7081070</ArticleId><ArticleId IdType="pubmed">25381058</ArticleId></ArticleIdList></Reference><Reference><Citation>Yanning L., Ding X.L., James P.T. Lipid rafts are involved in SARS-CoV entry into Vero E6 cells. Biochem. Biophys. Res. Comm. 2008;369:344–349.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7092920</ArticleId><ArticleId IdType="pubmed">18279660</ArticleId></ArticleIdList></Reference><Reference><Citation>Bianka V., Milo M., Tamás S., Szabolcs B. Molecular interactions in remdesivir-cyclodextrin systems. J. Pharm. Biomed. Anal. 2022;209:114482.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8609759</ArticleId><ArticleId IdType="pubmed">34856493</ArticleId></ArticleIdList></Reference><Reference><Citation>Lajos S., Istvan P., Tamas S. Sulfobutylether-beta-cyclodextrin-enabled antiviral remdesivir: Characterization of electrospun and lyophilized formulations. Carb. Pol. 2021;264:118011.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8025548</ArticleId><ArticleId IdType="pubmed">33910715</ArticleId></ArticleIdList></Reference><Reference><Citation>Gosselin-Grenet A.S., Mottet-Osman G., Roux L. From assembly to virus particle budding: Pertinence of the detergent resistant membranes. Virology. 2006;344:296–303. doi: 10.1016/j.virol.2005.09.035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2005.09.035</ArticleId><ArticleId IdType="pubmed">16229873</ArticleId></ArticleIdList></Reference><Reference><Citation>Laliberte J.P., McGinnes L.W., Peeples M.E., Morrison T.G. Integrity of membrane lipid rafts is necessary for the ordered assembly and release of infectious Newcastle disease virus particles. J. Virol. 2006;80:10652–10662. doi: 10.1128/JVI.01183-06.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01183-06</ArticleId><ArticleId IdType="pmc">PMC1641742</ArticleId><ArticleId IdType="pubmed">17041223</ArticleId></ArticleIdList></Reference><Reference><Citation>Jing L., Fang X., Yujie D., Jiawen Z., Yuan S., Danning L., Natthida S., Jiamiao H. A Review of Cyclodextrin Encapsulation and Intelligent Response for the Release of Curcumin. Polymers. 2022;14:5421. doi: 10.3390/polym14245421.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/polym14245421</ArticleId><ArticleId IdType="pmc">PMC9786145</ArticleId><ArticleId IdType="pubmed">36559788</ArticleId></ArticleIdList></Reference><Reference><Citation>Susana S.B., Jéssica S.B., Nádia E.S., Firas E.-S., Filipe A.A. Cyclodextrins in Antiviral Therapeutics and Vaccines. Pharmaceutics. 2021;13:409. doi: 10.3390/pharmaceutics13030409.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pharmaceutics13030409</ArticleId><ArticleId IdType="pmc">PMC8003769</ArticleId><ArticleId IdType="pubmed">33808834</ArticleId></ArticleIdList></Reference><Reference><Citation>Jitendra W., Niranjan G.K., Sonia G., Swetha R., Abhay P., Yury A.R. Recent Advances in Host–Guest Self-Assembled Cyclodextrin Carriers: Implications for Responsive Drug Delivery and Biomedical Engineering. Adv. Funct. Mater. 2020;30:1909049.</Citation></Reference><Reference><Citation>European Medicines Agency . Cyclodextrins Used as Excipients (EMA/CHMP/495747/2013) European Medicines Agency; Amsterdam, The Netherlands: 2017.</Citation></Reference><Reference><Citation>Cyclodextrin News . Gilead Uses SBECD-Enabled Remdesivir (GS Liqui-Solid 5734) for Treating the First Case of the Novel Coronavirus in the United States. Cyclodextrin News; Dunkerque, France: 2020.</Citation></Reference><Reference><Citation>Goyal G., Vavia P. Complexation approach for fixed-dose tablet formulation of lopinavir and ritonavir: An anomalous relationship between stability constant, dissolution rate and saturation solubility. J. Incl. Phenom. Macrocycl. Chem. 2012;73:75–85. doi: 10.1007/s10847-011-0022-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10847-011-0022-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Sevukarajan M., Bachala T., Nair R. Novel inclusion complexes of Oseltamivir Phosphate with beta-cyclodextrin: Physicochemical characterization. J. Pharm. Sci. Res. 2010;2:583–589.</Citation></Reference><Reference><Citation>Rajaram R., Sonaimuthu M., Sekar A., Eun H.C., Fatiha M., Neour L., Yong R.L. Water-soluble inclusion complexes for a novel anti-viral agent with low toxicity; Oseltamivir with the β-cyclodextrins. J. Mol. Liq. 2022;366:120297.</Citation></Reference><Reference><Citation>Rajaram R., Sonaimuthu M., Sekar A., Fatiha M., Neour L., Kuppusamy M., Yong R.L. A novel and water-soluble material for coronavirus inactivation from oseltamivir in the cavity of methyl and sulfated-β-cyclodextrins through inclusion complexation. J. Pharm. Biomed. Anal. 2022;221:115057.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9476363</ArticleId><ArticleId IdType="pubmed">36126612</ArticleId></ArticleIdList></Reference><Reference><Citation>Arumugam P., Samikannum P., Rajaram R. Encapsulation of quercetin in β-cyclodextrin and (2-hydroxypropyl)-β-cyclodextrin cavity: In-vitro cytotoxic evaluation. J. Macromol. Sci. A. 2017;54:894–901.</Citation></Reference><Reference><Citation>Ono A., Freed E.O. Plasma membrane rafts play a critical role in HIV-1 assembly and release. Proc. Natl. Acad. Sci. USA. 2001;98:13925–13930. doi: 10.1073/pnas.241320298.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.241320298</ArticleId><ArticleId IdType="pmc">PMC61143</ArticleId><ArticleId IdType="pubmed">11717449</ArticleId></ArticleIdList></Reference><Reference><Citation>Pickl W.F., Pimentel-Muinos F.X., Seed B. Lipid rafts and pseudotyping. J. Virol. 2001;75:7175–7183. doi: 10.1128/JVI.75.15.7175-7183.2001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.75.15.7175-7183.2001</ArticleId><ArticleId IdType="pmc">PMC114446</ArticleId><ArticleId IdType="pubmed">11435598</ArticleId></ArticleIdList></Reference><Reference><Citation>Piñeiro A., Pipkin J., Vince Antle V., Garcia-Fandino R. Remdesivir interactions with sulphobutylether-b- cyclodextrins: A case study using selected substitution patterns. J. Mol. Liq. 2022;346:117157. doi: 10.1016/j.molliq.2021.117157.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molliq.2021.117157</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajaram R., Sundararajulu K., Krishnamoorthy S., Meenakshisundaram M. Photophysical and photoprototropic characteristics of phenothiazine in aqueous and β-cyclodextrin media. J. Lumin. 2016;168:245–255.</Citation></Reference><Reference><Citation>Ángel P., James P., Vince A., Rebeca G. -F.; Aggregation versus inclusion complexes to solubilize drugs with cyclodextrins. A case study using sulphobutylether-β-cyclodextrins and remdesivir. J. Mol. Liq. 2021;343:117588.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8447550</ArticleId><ArticleId IdType="pubmed">34548723</ArticleId></ArticleIdList></Reference><Reference><Citation>Yumeng Z., Zhouming Z., Kai W., Kangjie L., Cai Y., Lin L., Xia S., Tengfei L., Xiaodi G., Haiyan L., et al. Molecular docking assisted exploration on solubilization of poorly soluble drug remdesivir in sulfobutyl ether-tycyclodextrin. AAPS Open. 2022;8:9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9035334</ArticleId><ArticleId IdType="pubmed">35498163</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamas K., Kitti K., Zoltan V., Peter N., Gyorgy P., Florina Z. Veklury® (remdesivir) for-mulations inhibit initial membrane-coupled events of SARS-CoV-2 infection due to their sulfobutylether-β-cyclodextrin content. Br. J. Pharmacol. 2023;180:2064–2084.</Citation><ArticleIdList><ArticleId IdType="pubmed">36848880</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhengdong Y., Deqing X., Kah H.J.L., Thomas T., Rita H., Bryan P., Yu-Hui A.F., Eric J., Marsha L.L., Habibi G., et al. The determination of Sulfobutylether -Cyclodextrin Sodium (SBECD) by LC-MS/MS and its application in remdesivir pharmacokinetics study for pediatric patients. J. Pharm. Biomed. Anal. 2022;212:114646.</Citation><ArticleIdList><ArticleId IdType="pubmed">35180564</ArticleId></ArticleIdList></Reference><Reference><Citation>Saraswati R.P., Sutriyo Ratika R. Preparation, Cellular Uptake, and Cytotoxic Evaluation of Remdesivir-Hydroxypropyl-β-Cyclodextrin Inclusion Complex. Biomed. Pharmacol. J. 2022;2:15</Citation></Reference><Reference><Citation>Robert L.P. Mouse models of human disease. Evol. Med. Public Health. 2016;2016:170–176.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4875775</ArticleId><ArticleId IdType="pubmed">27121451</ArticleId></ArticleIdList></Reference><Reference><Citation>Prabu S., Sivakumar K., Kothai Nayaki S., Rajamohan R. Host-guest interaction of cytidine in β-cyclodextrin microcavity: Characterization and docking study. J. Mol. Liq. 2016;219:967–974. doi: 10.1016/j.molliq.2016.04.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molliq.2016.04.017</ArticleId></ArticleIdList></Reference><Reference><Citation>Viswalingam M., Prabu S., Sivakumar K., Rajamohan R. Spectral characteristics of desipramine in β-cyclodextrin cavity through inclusion complex. J. Macro Sci. Part. A. 2016;53:781–790. doi: 10.1080/10601325.2016.1237817.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/10601325.2016.1237817</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajamohan R., Kothai Nayaki S., Swaminathan M. Investigation on association behavior between 1-Aminoisoquinoline and β-Cyclodextrin in solution and solid state. J. Mol. Liq. 2016;220:918–925. doi: 10.1016/j.molliq.2016.04.118.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molliq.2016.04.118</ArticleId></ArticleIdList></Reference><Reference><Citation>Praveena A., Prabu S., Madi F., Rajamohan R. Theoretical investigation of inclusion complexes of 3-hydroxyflavone andquercetin as guests with native and modified β-cyclodextrins as hosts. Polycycl. Aromat. Compd. 2023;43:141–153. doi: 10.1080/10406638.2021.2009526.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/10406638.2021.2009526</ArticleId></ArticleIdList></Reference><Reference><Citation>Samuel T., Jones V. Modified cyclodextrins as broad-spectrum antivirals. Sci. Adv. 2020;6:eaax9318.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6989148</ArticleId><ArticleId IdType="pubmed">32064341</ArticleId></ArticleIdList></Reference><Reference><Citation>Okimoto K., Rajewski R.A., Uekama K., Jona J.A., Stella V.J. The interaction of charged and uncharged drugs with neutral (HP-beta-CD) and anionically charged (SBE7-beta-CD) beta-cyclodextrins. Pharm. Res. 1996;13:256–264. doi: 10.1023/A:1016047215907.</Citation><ArticleIdList><ArticleId IdType="doi">10.1023/A:1016047215907</ArticleId><ArticleId IdType="pubmed">8932446</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>